Related Experiment Video
Updated: Apr 20, 2026
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
Promising new treatment targets in patients with fibrosing lung disorders
Martina Sterclova1, Martina Vasakova1
1Martina Sterclova, Martina Vasakova, Department of Respiratory Medicine, Thomayer Hospital and 1 Medical Faculty of Charles University, Prague 14000, Czech Republic.
Abstract:
The processes of lung fibrogenesis and fibrotic healing are common to a number of conditions with different etiologies. The lungs are the only affected organ in some cases, whereas in others, several organ systems are involved. Therapeutic options can be discussed from various perspectives. In this review, we address the localization of therapeutic targets with regard to cell compartments, including secreted ligands, cell surface, plasma membrane-cytosol interplay, cytosol and nucleus. Complex approach using stem cell therapy is also discussed. As the prognosis of patients with these disorders remains grim, treatment combinations targeting different molecules within the cell should sometimes be considered. It is reasonable to assume that blocking specific pathways will more likely lead to disease stabilization, while stem cell-based treatments could potentially restore lung architecture. Gene therapy could be a candidate for preventive care in families with proven specific gene polymorphisms and documented familial lung fibrosis. Chronobiology, that takes into account effect of circadian rhythm on cell biology, has demonstrated that timed drug administration can improve treatment outcomes. However, the specific recommendations for optimal approaches are still under debate. A multifaceted approach to interstitial lung disorders, including cooperation between those doing basic research and clinical doctors as well as tailoring research and treatment strategies toward (until now) unmet medical needs, could improve our understanding of the diseases and, above all, provide benefits for our patients.
Insights
Lung fibrogenesis treatments are being explored, including targeting cellular compartments, stem cells, and gene therapy. A multifaceted approach may improve outcomes for interstitial lung disorders.
Area of Science:
- Pulmonology
- Cell Biology
- Pharmacology
Background:
- Lung fibrogenesis and fibrotic healing are complex processes underlying various conditions.
- These fibrotic disorders can be localized to the lungs or involve multiple organ systems.
- Current therapeutic options for interstitial lung disorders have limited efficacy, with grim prognoses.
Purpose of the Study:
- To review therapeutic targets for lung fibrogenesis based on their cellular localization.
- To discuss the potential of stem cell therapy, gene therapy, and chronobiology in treating fibrotic lung diseases.
- To advocate for a multifaceted research and treatment strategy for interstitial lung disorders.
Main Methods:
- Review of literature on therapeutic targets within different cell compartments (secreted ligands, cell surface, cytosol, nucleus).
- Discussion of complex therapeutic approaches including stem cell therapy and gene therapy.
- Consideration of chronobiology and timed drug administration.
Main Results:
- Therapeutic targets can be localized to various cellular compartments, offering diverse treatment strategies.
- Stem cell-based treatments show potential for restoring lung architecture.
- Gene therapy may be beneficial for specific familial lung fibrosis cases.
- Timed drug administration, informed by chronobiology, can enhance treatment outcomes.
Conclusions:
- A combination of therapies targeting different molecular pathways may be necessary for disease stabilization.
- Integrating basic research with clinical practice is crucial for advancing treatment for interstitial lung disorders.
- Addressing unmet medical needs through tailored strategies is essential for patient benefit.
Related Concept Videos
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...